Commodore Capital completely exited its 3.2 million share position in Viridian Therapeutics (worth $69 million) on February 17, 2026, reducing the holding from 3.4% of the fund's assets to zero. This comes despite Viridian's stock being up 75% over the past year and entering a catalyst-heavy 2026 with FDA approval decisions and Phase 3 data expected. The exit suggests the fund may be taking profits after the strong rally or reallocating capital to other clinical-stage biotech names.

Commodore Capital increased its stake in Spyre Therapeutics by 400,161 shares ($10.46 million) in Q4, bringing its total position to $78.24 million (5.21% of AUM). SYRE stock has surged 63% over the past year, significantly outperforming the S&P 500's 13% gain. The preclinical biotech company, focused on inflammatory bowel disease treatments, has a strong balance sheet with $757 million in cash and expects runway into H2 2028, with six Phase 2 readouts expected in 2026.

The Irish High Court has sanctioned Avadel Pharmaceuticals' scheme of arrangement without modification, allowing Alkermes to acquire Avadel's entire issued share capital. The transaction is expected to close on February 12, 2026, with trading of Avadel shares on Nasdaq halting on February 11, 2026.

Avadel Pharmaceuticals shareholders have approved the proposed acquisition by Alkermes plc through a scheme of arrangement. The approval was overwhelming, with 97.41% of votes cast in favor at the scheme meeting and 96.53% approval at the extraordinary general meeting. The transaction is expected to proceed pending satisfaction of remaining conditions.

Avadel Pharmaceuticals announced the mailing of a proxy statement regarding its proposed acquisition by Alkermes, with scheme and extraordinary general meetings scheduled for January 12, 2026, to vote on the transaction.

Multiple corporate deals and strategic investments highlighted this week, including Kirin's potential Four Roses acquisition, quantum computing companies seeking U.S. government equity stakes, and Six Flags attracting activist investor interest with Travis Kelce's involvement.

Law firm Monteverde & Associates is investigating the proposed sale of Avadel Pharmaceuticals to Alkermes, where shareholders will receive $18.50 per share plus a potential additional $1.50 contingent on FDA approval of LUMRYZ™ by end of 2028.

Alkermes agreed to acquire Avadel Pharmaceuticals for up to $20 per share, valuing the deal at $2.1 billion. The acquisition includes the narcolepsy drug Lumryz and is expected to close in Q1 2026, with potential additional payment contingent on FDA approval.

Alkermes (NASDAQ:ALKS) was analyzed by 6 analysts in the last quarter, with a range of viewpoints from bullish to bearish. The analysts provided an average 12-month price target of $36.33, with a high of $48.00 and a low of $31.00. The article also provides financial insights into Alkermes, including its market capitalization, revenue growth, net margin, and debt management.

Orchestra BioMed Holdings, Inc. (OBIO) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Alkermes (ALKS) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

Sector ETF report for PSCH